Lentivirus-mediated gene transfer to the eye

慢病毒介导的基因转移到眼睛

• 批准号: nhmrc : 375104
• 负责人: A/Pr Donald Anson
• 金额: $ 34.63万
• 依托单位: Flinders University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/lentivirus-mediated-gene-transfer-eye/98004
• 关键词: Lentivirus; mediated; gene; transfer; eye

Blindness exerts major physical, emotional and economic constraints and hardship upon the sufferer. Transplant surgery can restore vision to many people who are visually impaired as a result of disease affecting the front of the eye. The transplant itself is taken from the eye of a person who has died, after consent from the donor's family. Our goal is to improve the outcome for patients who require transplants of tissue to the front of the eye, in order to restore their vision or to relieve pain. Our work is predicated on the finding that unwanted immune responses are the major cause of graft failure in such patients. The recipient recognizes the grafted tissue as being foreign, and rejects it. Treatment with conventional systemic drugs appears to hold little promise for further improvements in outcome, but gene therapy applied to the donor tissue may provide a safe and effective way of reducing transplant failure. Gene therapy can be undertaken on the donor tissue in the laboratory, prior to transplantation surgery. In this project, we will assess the suitability of a new method of modifying the transplant. All of the work will be performed on the laboratory bench, or in experimental animals.

失明对患者造成了重大的身体、情感和经济限制和困难。移植手术可以使许多因眼睛前部疾病而视力受损的人恢复视力。移植本身是在征得捐赠者家属同意后，从死者的眼睛中取出的。我们的目标是改善需要将组织移植到眼睛前部的患者的结果，以恢复他们的视力或减轻疼痛。我们的工作是基于这样的发现，即不必要的免疫反应是这类患者移植失败的主要原因。接受者认识到移植的组织是外来的，并拒绝它，用常规的全身药物治疗似乎没有希望进一步改善结果，但基因治疗应用于供体组织可能提供一个安全和有效的方法来减少移植失败。在移植手术之前，可以在实验室中对供体组织进行基因治疗。在这个项目中，我们将评估一种新的修改移植方法的适用性。所有的工作都将在实验室工作台或实验动物中进行。